India Maintains Status Quo On Compulsory Licensing Provisions
This article was originally published in The Pink Sheet Daily
Indian generics industry, multi-national company lobbies welcome moves to keep flexibility, but doubts linger regarding future investments.
You may also be interested in...
MUMBAI - Merck & Co.'s HIV integrase inhibitor Isentress (raltegravir) may have been a big success across many markets, but in India the anti-AIDS drug may be short of its mark. Leading home-grown company Cipla Ltd. has taken the route of applying for a "voluntary license" for the drug to New Jersey-headquartered Merck because Cipla says it is not reaching needy patients in India and it is priced exorbitantly
MUMBAI - After soliciting views from stakeholders on a "discussion paper" to outline conditions in which a compulsory license could be invoked, India's Department of Industrial Policy and Promotion is now trying to figure out what to do
Indian Firms Must Be In Indian Hands, Says Government Paper; Highlights Threats to Compulsory Licensing And Drug Pricing
MUMBAI - Ambitions of leading multinational companies for a long-term positioning in India through acquisition of generic companies may face rigid policy restrictions from a government concerned about monopoly-dictated pricing for needed drugs